Submitted for Publication: February 21, 2014; final revision received May 7, 2014; accepted May 12, 2014.
Published Online: September 18, 2014. doi:10.1001/jamaophthalmol.2014.3591.
Study concept and design: Yannuzzi, Klufas, Kaminsky, Crystal, D’Amico, Kiss.
Acquisition, analysis, or interpretation of data: Yannuzzi, Klufas, Quach, Beatty, Kaminsky, Crystal, Kiss.
Drafting of the manuscript: Yannuzzi, Klufas, Quach, Kaminsky, Crystal, Kiss.
Critical revision of the manuscript for important intellectual content: Yannuzzi, Klufas, Beatty, Kaminsky, Crystal, D’Amico, Kiss.
Statistical analysis: Yannuzzi, Klufas, Beatty, Kaminsky, Crystal, Kiss.
Obtained funding: Crystal, Kiss.
Administrative, technical, or material support: Klufas, Quach, Crystal, D’Amico.
Study supervision: Klufas, Kaminsky, Crystal, D’Amico, Kiss.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr D’Amico reported receiving support from Ophthotech Inc, Neurotech Inc, and Genentech Inc outside of this work. Dr Kiss serves as a consultant for Genentech/Roche, the manufacturer of bevacizumab. Dr Kiss has also received support from Regeneron, Allergan, Alimera, Thrombogenics, and Optos outside of this work. No other disclosures were reported.
Funding/Support: The research presented here was supported in part by an unrestricted grant to the Weill Cornell Department of Ophthalmology from Research to Prevent Blindness.
Role of the Funder/Sponsor: Research to Prevent Blindness had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank Harry W. Flynn Jr, MD, for his review and feedback on the manuscript. He did not receive compensation for his contribution.